Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2016

Share Based Compensation Option And Incentive Plan [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following is a summary of stock option activity for the three months ended March 31, 2015 and 2016:

	Number of Options		Weighted- Average Exercise Price		Weighted-Average Contractual Life (In Years)
Three months ended March 31, 2015
Outstanding at beginning of year		752,372	$	0.91		4.55
Granted		435,393		5.80		9.88
Exercised		(23,075)	$	0.65
Expired		(8,600)	$	0.65
Outstanding at end of period		1,156,090	$	2.69		5.05

Exercisable at end of period		827,529	$	2.46		6.87

Vested and expected to vest at end of period		827,529	$	2.46		6.87

	Number of Options		Weighted- Average Exercise Price		Weighted-Average Contractual Life (In Years)
Three months ended March 31, 2016
Outstanding at beginning of year		1,277,367	$	2.75		4.94
Granted		210,525		2.91		9.91
Exercised		-	$	-
Expired		-	$	-
Outstanding at end of period		1,487,892	$	2.80		5.48

Exercisable at end of period		975,881	$	2.68		5.51

Vested and expected to vest at end of period		975,881	$	2.68		5.51

Employee and Non Employee Service Share Based Compensation Allocation off Recognized Period Costs [Table Text Block]

The total stock-based compensation expense for employees and non-employees is included in the accompanying condensed consolidated statements of operations and as follows:

	Three Months Ended
	March 31,
	2016		2015
Research and development	$	18,459	$	174,586
General and administrative		94,901		309,954
	$	113,360	$	484,540